CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.

Blood Adv · 2023 · PMC10598487 · PMID 37648670

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

showed a trendP = .09so close (0.05 < p ≤ 0.1)

Ex vivo drug treatment results for the anti-CD38 antibody that were obtained clinically showed a trend toward a significant correlation with the re-treatment clinical response ( R = 0.59; P = .09; Figure 4 B) despite cell number limitations preventing analysis of the other drugs the patients received in their treatment combinations.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.